A Convolutional Neural Network Uses Microscopic Images to Differentiate between Mouse and Human Cell Lines and Their Radioresistant Clones.

Journal: Cancer research
Published Date:

Abstract

: Artificial intelligence (AI) trained with a convolutional neural network (CNN) is a recent technological advancement. Previously, several attempts have been made to train AI using medical images for clinical applications. However, whether AI can distinguish microscopic images of mammalian cells has remained debatable. This study assesses the accuracy of image recognition techniques using the CNN to identify microscopic images. We also attempted to distinguish between mouse and human cells and their radioresistant clones. We used phase-contrast microscopic images of radioresistant clones from two cell lines, mouse squamous cell carcinoma NR-S1, and human cervical carcinoma ME-180. We obtained 10,000 images of each of the parental NR-S1 and ME-180 controls as well as radioresistant clones. We trained the CNN called VGG16 using these images and obtained an accuracy of 96%. Features extracted by the trained CNN were plotted using t-distributed stochastic neighbor embedding, and images of each cell line were well clustered. Overall, these findings suggest the utility of image recognition using AI for predicting minute differences among phase-contrast microscopic images of cancer cells and their radioresistant clones. SIGNIFICANCE: This study demonstrates rapid and accurate identification of radioresistant tumor cells in culture using artifical intelligence; this should have applications in future preclinical cancer research.

Authors

  • Masayasu Toratani
    Department of Radiation Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Masamitsu Konno
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Ayumu Asai
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Jun Koseki
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Koichi Kawamoto
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Keisuke Tamari
    Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Zhihao Li
    Heilongjiang University of CM, Harbin 150040, China.
  • Daisuke Sakai
    Department of Orthopedics Surgery, Surgical Science, Tokai University School of Medicine, Isehara, Japan.
  • Toshihiro Kudo
    Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Taroh Satoh
    Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Katsutoshi Sato
    Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, QST, Inage, Chiba, Japan.
  • Daisuke Motooka
    Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Daisuke Okuzaki
    Laboratory of Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, The University of Osaka, Osaka 565-0871, Japan.
  • Yuichiro Doki
    Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.
  • Masaki Mori
    Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.
  • Kazuhiko Ogawa
    Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Hideshi Ishii
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. kogawa@radonc.med.osaka-u.ac.jp hishii@gesurg.med.osaka-u.ac.jp.